StreetInsider.com News Articles

Form D HCW Biologics Inc.

Mon, 08 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260608/26617452.html

Form D HCW Biologics Inc.

Mon, 08 Jun 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260608/26617452.html

HCW Biologics (HCWB) files for 5.69M share offering by selling stockholders

Mon, 08 Jun 2026 10:13:34 -0400

HCW Biologics (NASDAQ: HCWB) has filed for up to 5,693,950 share offering by selling stockholders.

HCW Biologics (HCWB) files for 5.69M share offering by selling stockholders

Mon, 08 Jun 2026 10:13:34 -0400

HCW Biologics (NASDAQ: HCWB) has filed for up to 5,693,950 share offering by selling stockholders.

Form S-1 HCW Biologics Inc.

Mon, 08 Jun 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26615593.html

Form S-1 HCW Biologics Inc.

Mon, 08 Jun 2026 10:10:00 -0400

si-local-file:///var/storage/secattach/20260608/26615593.html

Form 8-K HCW Biologics Inc. For: May 29

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579237.html

Form 8-K HCW Biologics Inc. For: May 29

Mon, 01 Jun 2026 07:30:00 -0400

si-local-file:///var/storage/secattach/20260601/26579237.html

HCW Biologics Inc. (HCWB) PT Raised to $5 at Maxim Group

Thu, 28 May 2026 14:34:05 -0400

Maxim Group analyst Michael Okunewitch raised the price target on HCW Biologics Inc. (NASDAQ: HCWB) to $5.00 (from $2.00) while maintaining a Buy rating.

Form 4 HCW Biologics Inc. For: May 22 Filed by: Wong Hing C

Wed, 27 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260527/26559596.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: Wong Hing C

Wed, 27 May 2026 19:26:00 -0400

si-local-file:///var/storage/secattach/20260527/26559596.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: GARRETT SCOTT T

Wed, 27 May 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260527/26559592.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: GARRETT SCOTT T

Wed, 27 May 2026 19:25:00 -0400

si-local-file:///var/storage/secattach/20260527/26559592.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: Byam Rebecca

Wed, 27 May 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260527/26559589.html

Form 4 HCW Biologics Inc. For: May 22 Filed by: Byam Rebecca

Wed, 27 May 2026 19:24:00 -0400

si-local-file:///var/storage/secattach/20260527/26559589.html

Form 8-K HCW Biologics Inc. For: May 21

Wed, 27 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26553822.html

Form 8-K HCW Biologics Inc. For: May 21

Wed, 27 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260527/26553822.html

HCW Biologics regains rights to CAR-T therapy reagents from Wugen

Wed, 27 May 2026 07:45:43 -0400

HCW Biologics Inc. (NASDAQ: HCWB) announced it exercised its option to regain full ex vivo rights to HCW9206 and HCW9201, two commercial-ready compounds as reagents, from licensee Wugen Inc. The company acquired these rights at no cost and retained a nonrefundable upfront license fee, including 2.2 million shares of Wugen common stock.

The compounds target the CAR-T immunotherapy market. Recent data published in Science Advances indicate that HCW9206, a multi-cytokine fusion protein reagent, may offer an approach to producing CAR-T cells with enhanced function for immunotherapy applications.

According to the press release, HCW9206 generates a CAR-T population enriched for T-memory stem cells,

HCW Biologics regains rights to CAR-T therapy reagents from Wugen

Wed, 27 May 2026 07:45:43 -0400

According to the press release, HCW9206 generates a CAR-T population enriched for T-memory stem cells,

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Wed, 27 May 2026 07:45:00 -0400

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market

Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes

Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers

MIRAMAR, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing first-in-class fusion immunotherapeutics for autoimmune diseases, cancer, and senescence-associated dysplasia, today announced that it has exercised its option to

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Wed, 27 May 2026 07:45:00 -0400

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market

Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes

Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Wed, 27 May 2026 07:45:00 -0400

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market

Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes

Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers

HCW Biologics Exercised Option to Regain Full Rights for Two Commercial-Ready Reagents from Wugen

Wed, 27 May 2026 07:45:00 -0400

Positions the Company to participate in fast-growing, multi-billion-dollar CAR-T immunotherapy market

Recently published data suggest that HCW9206 may reduce CAR-T production costs and improve therapeutic efficacies, with the potential to support curative outcomes

Company plans to commercialize the reagents through corporate partners focused on CAR-T and NK-cell therapies, including developers and manufacturers

HCW Biologics raises $4 million in private placement with E.F. Hutton

Fri, 22 May 2026 16:03:08 -0400

HCW Biologics Inc. (NASDAQ: HCWB) completed a $4.0 million private placement with E.F. Hutton & Co. serving as the sole placement agent, according to a company statement.

The offering closed on May 21, 2026. HCW Biologics, a clinical-stage biopharmaceutical company, develops fusion immunotherapeutics for diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions.

The company plans to use the net proceeds to continue clinical trials for HCW9302, advance IND-enabling studies for its T-Cell Engager HCW11-018b, and its second-generation immune checkpoint inhibitor HCW11-040. Funds will also support general corporate purposes, including debt repayment and settlements.

"We are pleased to have partnered

E.F. Hutton & Co. Serves as Sole Placement Agent on HCW Biologics Inc. $4.0 Million Private Placement

Fri, 22 May 2026 16:02:37 -0400

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), an investment banking and financial advisory firm headquartered in New York City, today announced that it acted as the sole placement agent in connection with a $4.0 million private placement for HCW Biologics Inc. (“HCW Biologics” or the “Company”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics designed to treat diseases driven by chronic inflammation, including autoimmune disorders, cancer, and senescence-associated conditions.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton & Co., commented, “We are pleased